Pemafibrate - Kowa Pharmaceutical

Drug Profile

Pemafibrate - Kowa Pharmaceutical

Alternative Names: K 877; Parmodia

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kowa Pharmaceutical
  • Class Antihyperlipidaemics; Benzoxazoles; Butyric acids; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Hyperlipidaemia
  • Phase III Dyslipidaemias; Hypertriglyceridaemia
  • Phase I Primary biliary cirrhosis

Most Recent Events

  • 22 Nov 2017 Kowa Pharmaceutical plans a phase II trial in Non-alcoholic fatty liver disease in Japan (NCT03350165)
  • 17 Nov 2017 Kowa Company and Jaeb Center for Health Research plan the phase III PROMINENT-Eye Ancillary Study (Protocol AD) trial for Diabetic retinopathy in USA (PO) (NCT03345901)
  • 01 Sep 2017 Phase-I clinical trials in Primary biliary cirrhosis in Japan (PO) (JapicCTI-173728)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top